PacBio FY2025 amortization of acquired intangible assets rises to USD 364.5 million (19.3x)

Reuters02-26
PacBio FY2025 amortization of acquired intangible assets rises to USD 364.5 million (19.3x)

PacBio reported FY 2025 revenue of USD 160.0 million (+4%), with gross profit of USD 45.8 million (+23%). Operating loss widened to USD 553.9 million (+17%) and net loss was USD 546.4 million. Cash, cash equivalents, and investments totaled USD 279.5 million at Dec. 31, 2025 (-28%), and cash used in operating activities was USD 111.2 million in FY 2025. FY 2025 revenue included USD 82.0 million of consumables revenue, USD 53.8 million of instrument revenue, and USD 24.2 million of service and other revenue; service and other revenue rose 36% to USD 24.2 million, primarily driven by an increase in Revio service contracts. Instrument revenue declined due to fewer Revio systems sold (61 units in FY 2025 versus 97 units in FY 2024), partially offset by Vega sales (140 units sold following its commercial launch in Q4 2024). PacBio also recorded USD 359.3 million of accelerated amortization in Q1 2025 tied to developed technology from the 2021 Omniome acquisition, reflecting a revised estimate that the asset will no longer generate economic benefit. In corporate updates, PacBio said it completed an asset disposition on Jan. 30, 2026, selling certain intellectual property and other assets related to its short-read DNA sequencing technology for USD 50.0 million in cash, resulting in approximately USD 48.1 million in net cash proceeds. Looking to 2026, PacBio outlined priorities including accelerating samples onto Revio through SPRQ-Nx chemistry and application kits, expanding Vega’s capabilities via software improvements, and progressing its clinical strategy and data-driven interpretation initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001299130-26-000034), on February 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment